TheTechno Optimist.

StoryResearch

NEJM publishes REDEFINE 1 and REDEFINE 2: 20.4% weight loss in obesity and 13.7% with type 2 diabetes at 68 weeks

Novo NordiskCagriSema

NEJM published Novo's two main Phase 3 trials of CagriSema, a weekly semaglutide plus amylin-analogue shot. REDEFINE 1 (3,417 adults with obesity) showed 20.4% weight loss at 68 weeks versus 3.0% on placebo; REDEFINE 2 (1,206 with type 2 diabetes) showed 13.7% versus 3.4%. Gastrointestinal side effects were common but mostly mild.

  • REDEFINE 1: 20.4% weight loss vs. 3.0% placebo in 3,417 adults with obesity (68 weeks).
  • REDEFINE 2: 13.7% weight loss vs. 3.4% placebo in 1,206 with type 2 diabetes (68 weeks).
  • CagriSema combines cagrilintide (amylin analogue) and semaglutide (GLP-1).
  • GI adverse events in 79.6% of CagriSema patients but mostly mild to moderate and transient.
Read the original · Paper Biotech

More on CagriSema

Primer